Diabetic retinopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:04:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Diabetic retinopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-anxv-in-patients-with-diabetic-retinopathy-or-retinal-vein-occlusion/ Wed, 29 Apr 2026 15:09:49 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-anxv-in-patients-with-diabetic-retinopathy-or-retinal-vein-occlusion/ This study focuses on two eye conditions: Diabetic Retinopathy, which is damage to the retina caused by diabetes, and Retinal Vein Occlusion, a condition where a blood vessel in the eye becomes blocked. The purpose of the study is to evaluate the safety and tolerability of a treatment called ANXV, which is a recombinant human Annexin A5 protein. This medication will be given through an intravenous infusion, meaning it is delivered directly into a vein.

During the study, participants will receive the medication and will be monitored for any side effects or how their bodies react to the treatment. The process involves checking for anti-drug antibodies, which are substances the body might create to fight against a medication. Researchers will also look at various aspects of eye health and how the medication moves through the body.

]]> Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-3283142-in-reducing-urine-albumin-for-patients-with-chronic-kidney-disease/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-3283142-in-reducing-urine-albumin-for-patients-with-chronic-kidney-disease/ This clinical trial is focused on studying a condition known as chronic kidney disease, which affects the kidneys’ ability to filter waste from the blood. The trial will evaluate a new treatment called BAY 3283142, which is taken as a coated tablet. The purpose of the study is to learn how well this new drug works and how safe it is in reducing the amount of a protein called albumin in the urine of people with chronic kidney disease. Albumin in the urine is a sign that the kidneys are not working as well as they should.

Participants in the study will be randomly assigned to receive either the new drug BAY 3283142 or a placebo, in addition to their standard care. The study will last for 16 weeks, during which time the participants will take the medication orally. The researchers will monitor changes in the urine albumin-creatinine ratio, which is a measure used to assess kidney function. This will help determine the most effective dose of the new drug for future studies.

Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The study aims to find the best dose of BAY 3283142 to help reduce albumin in the urine, which could potentially improve kidney health in people with chronic kidney disease. The results of this study will help guide further research and development of this treatment.

]]> Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-somatostatin-eye-drops-for-patients-with-moderately-severe-to-severe-non-proliferative-diabetic-retinopathy/ Wed, 29 Apr 2026 14:26:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-somatostatin-eye-drops-for-patients-with-moderately-severe-to-severe-non-proliferative-diabetic-retinopathy/ This clinical trial is focused on studying Diabetic Retinopathy, a condition that affects the eyes of people with diabetes, leading to vision problems. The study is testing a new treatment called COLIRIOBCN070660, which is an eye drop containing the active substance somatostatin. Somatostatin is a type of protein that may help reduce or stop the damage to small blood vessels in the eye caused by diabetic retinopathy. The purpose of the study is to evaluate how effective these eye drops are in treating patients with moderately severe to severe non-proliferative diabetic retinopathy, a stage of the disease where new blood vessels have not yet started to grow.

Participants in the study will be randomly assigned to receive either the COLIRIOBCN070660 eye drops or a placebo, which looks like the real treatment but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The treatment will be administered twice daily for one year. Throughout the study, the number of small bulges in the blood vessels of the eye, known as microaneurysms, will be monitored to see if the treatment is effective in reducing or stopping their formation.

In addition to monitoring microaneurysms, the study will also look at other factors such as the number of small bleeds in the eye, changes in the thickness of the retina, and overall eye health using various imaging techniques. The study aims to provide valuable information on whether COLIRIOBCN070660 can help improve or maintain vision in people with diabetic retinopathy, potentially offering a new treatment option for this common complication of diabetes.

]]> Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ Wed, 29 Apr 2026 14:26:19 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ This clinical trial is focused on studying the handling and safety of a treatment called Aflibercept, which is used for various eye conditions. These conditions include neovascular age-related macular degeneration (a type of vision loss in older adults), diabetic macular edema (swelling in the retina due to diabetes), myopic choroidal neovascularization (abnormal blood vessel growth in the eye due to severe nearsightedness), retinal vein occlusion (blockage of veins in the retina), and diabetic retinopathy (damage to the retina caused by diabetes). The treatment is administered as a solution for injection using a pre-filled syringe, referred to as AVT06.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

]]> Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy https://clinicaltrials.eu/trial/study-on-bi-764524-for-patients-with-moderate-to-severe-diabetic-retinopathy/ Wed, 29 Apr 2026 14:23:21 +0000 https://clinicaltrials.eu/trial/study-on-bi-764524-for-patients-with-moderate-to-severe-diabetic-retinopathy/ This clinical trial is focused on studying a condition called diabetic retinopathy, which affects the eyes of people with diabetes. The trial will test a treatment called BI 764524, which is given as a solution for injection directly into the eye. The purpose of the study is to see if this treatment can help improve the condition of the eye in people with moderately-severe to severe non-proliferative diabetic retinopathy.

Participants in the study will receive either the BI 764524 treatment or a sham injection procedure, which is a procedure that mimics the injection but does not contain the active treatment. The study will last for 72 weeks, during which the safety and effectiveness of the treatment will be monitored. The main goal is to observe if there is a significant improvement in the eye condition after receiving the treatment.

Throughout the study, participants will have regular check-ups to monitor their eye health and any changes in their condition. The study aims to provide valuable information on whether BI 764524 can be a beneficial treatment option for people with diabetic retinopathy, potentially leading to better management of this eye condition.

]]>